Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks. / Furberg, Julie Funch; Andersen, Per Kragh; Scheike, Thomas; Ravn, Henrik.

I: Pharmaceutical Statistics, 2024.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Furberg, JF, Andersen, PK, Scheike, T & Ravn, H 2024, 'Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks', Pharmaceutical Statistics. https://doi.org/10.1002/pst.2382

APA

Furberg, J. F., Andersen, P. K., Scheike, T., & Ravn, H. (2024). Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2382

Vancouver

Furberg JF, Andersen PK, Scheike T, Ravn H. Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks. Pharmaceutical Statistics. 2024. https://doi.org/10.1002/pst.2382

Author

Furberg, Julie Funch ; Andersen, Per Kragh ; Scheike, Thomas ; Ravn, Henrik. / Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks. I: Pharmaceutical Statistics. 2024.

Bibtex

@article{1d29838946e64c13a248eb62161a4c84,
title = "Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks",
abstract = "In randomised controlled trials, the outcome of interest could be recurrent events, such as hospitalisations for heart failure. If mortality rates are non-negligible, both recurrent events and competing terminal events need to be addressed when formulating the estimand and statistical analysis is no longer trivial. In order to design future trials with primary recurrent event endpoints with competing risks, it is necessary to be able to perform power calculations to determine sample sizes. This paper introduces a simulation-based approach for power estimation based on a proportional means model for recurrent events and a proportional hazards model for terminal events. The simulation procedure is presented along with a discussion of what the user needs to specify to use the approach. The method is flexible and based on marginal quantities which are easy to specify. However, the method introduces a lack of a certain type of dependence. This is explored in a sensitivity analysis which suggests that the power is robust in spite of that. Data from a randomised controlled trial, LEADER, is used as the basis for generating data for a future trial. Finally, potential power gains of recurrent event methods as opposed to first event methods are discussed.",
author = "Furberg, {Julie Funch} and Andersen, {Per Kragh} and Thomas Scheike and Henrik Ravn",
note = "{\textcopyright} 2024 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.",
year = "2024",
doi = "10.1002/pst.2382",
language = "English",
journal = "Pharmaceutical Statistics",
issn = "1539-1604",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks

AU - Furberg, Julie Funch

AU - Andersen, Per Kragh

AU - Scheike, Thomas

AU - Ravn, Henrik

N1 - © 2024 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.

PY - 2024

Y1 - 2024

N2 - In randomised controlled trials, the outcome of interest could be recurrent events, such as hospitalisations for heart failure. If mortality rates are non-negligible, both recurrent events and competing terminal events need to be addressed when formulating the estimand and statistical analysis is no longer trivial. In order to design future trials with primary recurrent event endpoints with competing risks, it is necessary to be able to perform power calculations to determine sample sizes. This paper introduces a simulation-based approach for power estimation based on a proportional means model for recurrent events and a proportional hazards model for terminal events. The simulation procedure is presented along with a discussion of what the user needs to specify to use the approach. The method is flexible and based on marginal quantities which are easy to specify. However, the method introduces a lack of a certain type of dependence. This is explored in a sensitivity analysis which suggests that the power is robust in spite of that. Data from a randomised controlled trial, LEADER, is used as the basis for generating data for a future trial. Finally, potential power gains of recurrent event methods as opposed to first event methods are discussed.

AB - In randomised controlled trials, the outcome of interest could be recurrent events, such as hospitalisations for heart failure. If mortality rates are non-negligible, both recurrent events and competing terminal events need to be addressed when formulating the estimand and statistical analysis is no longer trivial. In order to design future trials with primary recurrent event endpoints with competing risks, it is necessary to be able to perform power calculations to determine sample sizes. This paper introduces a simulation-based approach for power estimation based on a proportional means model for recurrent events and a proportional hazards model for terminal events. The simulation procedure is presented along with a discussion of what the user needs to specify to use the approach. The method is flexible and based on marginal quantities which are easy to specify. However, the method introduces a lack of a certain type of dependence. This is explored in a sensitivity analysis which suggests that the power is robust in spite of that. Data from a randomised controlled trial, LEADER, is used as the basis for generating data for a future trial. Finally, potential power gains of recurrent event methods as opposed to first event methods are discussed.

U2 - 10.1002/pst.2382

DO - 10.1002/pst.2382

M3 - Journal article

C2 - 38509020

JO - Pharmaceutical Statistics

JF - Pharmaceutical Statistics

SN - 1539-1604

ER -

ID: 387020845